Navigation Links
Otix Global to Offer Franchise Opportunities in Australia
Date:5/25/2010

y experience disagreement or disputes with franchise owners which may impact the operation of the franchise operation; our systems of internal control with the franchisees may be ineffective; deterioration of economic conditions could harm our business or the business of our franchisees; we may be subject to litigation related to our franchise relationships; we may lose a large customer or suffer a reduction in orders from a large customer; we must have innovative, technologically superior products to compete effectively; our products, due to their complexity, may contain errors or defects that are only discovered after sales by our customers, thus harming our reputation and business; we may have issues with intellectual property; we may trigger a debt covenant default which could impact our working capital and potentially disrupt our operations; and we have important international operations, which expose us to a variety of risks including government reimbursement and foreign currency exchange fluctuations, that could impact sales and operating results. For additional information regarding the risks inherent in our business, please see "Factors That May Affect Future Performance" included in our Annual Report on Form 10-K for the year ended December 31, 2009, and Form 10-Q for the quarter ended March 31, 2010, as filed with the Securities and Exchange Commission.

We undertake no obligation to revise our forward-looking statements to reflect events or circumstances after the date hereof as a result of new information, future events or otherwise.


'/>"/>
SOURCE Otix Global, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
3. Directors Forum: PEPFAR and the Global AIDS Response
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
7. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
8. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
9. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
10. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
11. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... 30, 2014  Packaging Coordinators, Inc. (PCI) is pleased ... acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is ... the United Kingdom and operates ... and Tokyo , Japan. Penn Pharma ... and Commercial dosage form manufacturing, as well as Clinical ...
(Date:7/30/2014)... LAKE FOREST, Ill., July 30, 2014  Hospira, ... leading provider of injectable drugs and infusion technologies, ... June 30, 2014. Net sales for the quarter ... share were $0.72. (Adjusted* measures exclude specified items ... the attached schedules.) On a U.S. Generally Accepted ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25
... Thirteen Abstracts Will Be Featured at Annual Kidney Care ... leading provider of kidney care services for those diagnosed ... with DaVita Clinical Research(R), today announced that company representatives ... 2009 Spring Clinical Meetings scheduled for March 25-29, 2009 ...
... Pharmaceuticals,Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a ... it has been selected to present the ... to Assess the Safety,Pharmacokinetics (PK) and Pharmacodynamics ... Type 2 Diabetes (T2DM)" at the upcoming ...
Cached Medicine Technology:DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 2DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 3DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 4DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 5Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA) 2
(Date:7/30/2014)... The household income of its residents is the most ... rates of avoidable hospital visits conditions that could be ... settings if treated at an early stage, according to a ... Policy (CSHP). , An analysis of hospital billing records ... in New Jersey found that as an area,s per capita ...
(Date:7/30/2014)... The Hearing Aid Clinics industry is ... 2014. Following a multiyear drop during the recession, the ... expansion of private healthcare coverage and, ultimately, the improving ... Aid Clinics industry revenue will increase at an ... five years to 2014. , According to IBISWorld Industry ...
(Date:7/30/2014)... Francisco, California (PRWEB) July 30, 2014 ... reach USD 5,440.5 million by 2020, growing at an ... to a new study by Grand View Research, Inc. ... prevalence of deafness is expected to serve this market ... usage rates of 100% digital hearing aid technology and ...
(Date:7/30/2014)... genetic mutation linked to obesity respond differently to pictures ... do not have the genetic mutation, according to a ... of Clinical Endocrinology & Metabolism ( JCEM ). ... typically results from a combination of eating too much, ... consumption of appetizing foods that are high in calories ...
(Date:7/30/2014)... died of a caffeine overdose in May highlighted the ... To help prevent serious health problems that can arise ... toward a rapid, at-home test to detect even low ... breast milk. Their report appears in ACS, Journal ... and colleagues note that caffeine,s popularity as a "pick-me-up" ...
Breaking Medicine News(10 mins):Health News:Income is a major driver of avoidable hospitalizations across New Jersey 2Health News:Income is a major driver of avoidable hospitalizations across New Jersey 3Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 2Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 4Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 5Health News:Brain response to appetizing food cues varies among obese people 2
... NASHVILLE, Tenn., Nov. 4 Healthcare Realty,Trust Incorporated ... stock cash,dividend for the quarter ended September 30, ... share, is payable on December 3, 2008 to ... Realty Trust is a real estate investment trust ...
... Covisint to Link Hospitals in Michigan,s "Thumb" ... and Improving Healthcare Delivery, Costs, DETROIT, ... ) today announced that its Covisint subsidiary ... now called,Michigan Thumb Health Information System (THIS). ...
... to reduce acute attacks by lowering serum urate levels, which ... high serum urate levels have been shown to lower the ... the safety and efficacy of febuxostat, a new drug being ... Europe, and a commonly used drug that has been around ...
... team led by Mitchell Lazar, MD, PhD, Director of ... University of Pennsylvania School of Medicine, has used state-of-the-art ... molecular "master regulator" of fat-cell biology is nestled in ... appear online this week in Genes & Development ...
... of animal free and defined cell culture media components will feature ... ... Fort Collins, CO (PRWEB) November 4, 2008 -- InVitria,s ... albumins in cell culture, will be featured at the 2nd International ...
... BeaconEquity.com announces the,availability of Trade Alerts on stocks ... the daily trading notes for free by visiting:, http://www.BeaconEquity.com/m ... (NYSE: WMT ),Advanced Medical Optics Inc. (NYSE: ... (NYSE: EXP ), QLogic Corp. (Nasdaq: QLGC ...
Cached Medicine News:Health News:Healthcare Realty Trust Announces Third Quarter Dividend 2Health News:Compuware Covisint to Securely Connect, Integrate Michigan's Thumb Health Information System 2Health News:Compuware Covisint to Securely Connect, Integrate Michigan's Thumb Health Information System 3Health News:Studies examine treatment for gout and the condition's protective effects 2Health News:Studies examine treatment for gout and the condition's protective effects 3Health News:Penn scientists map molecular regulation of fat-cell genetics 2Health News:InVitria to Present at WilBio's International Cell Engineering Meeting 2Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: WMT, EYE, ESRX, EXP, QLGC, NSM 2Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: WMT, EYE, ESRX, EXP, QLGC, NSM 3
Use the Mo Bio Vortex Adapter in conjunction with the Vortex Genie 2 for rapid bead beating procedures. Using the Mo Bio Vortex Adapter is an inexpensive alternative to other bead beating and Fast Pr...
... V-500 with Vacuum Controller V-800 and water-cooled secondary ... Model V-500 is a powerful ... vacuum applications. Applications Ideally suited ... Laboratory vacuum source for instruments including ...
... with Vacuum Controller V-800 Efficiently controls vacuum ... on and off as needed to maintain preset vacuum ... PTFE membrane vacuum pump designed to handle most vacuum ... with up to two rotary evaporators Laboratory ...
... BchiVac V-500 and water-cooled secondary condenser to ... a powerful PTFE membrane vacuum pump designed ... Ideally suited for use with ... Laboratory vacuum source for instruments including vacuum ...
Medicine Products: